ClinicalTrials.gg
RecruitingNCT06632379SPARKUpdated Oct 23, 2026

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

A Phase 4 interventional study of Atorvastatin 10 mg and Placebo in Hypertensive Disorders of Pregnancy, Preeclampsia and Gestational Hypertension, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ohio State University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 23, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Pre-Eclampsia by Ohio State University — 4 open to participants now, 4 under way, none of them phase 3. Pre-Eclampsia · Ohio State University.

Started
2025
the only one that year
Phase 4
5 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Pre-Eclampsia by Ohio State University, this one is the only one that started in 2025, is one of 5 in phase 4, and was the 10th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

4 of the 11 studies in Pre-Eclampsia by Ohio State University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 20 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pre-Eclampsia by Ohio State University, or all of them as a file.
02

Study summary

The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.

Read the detailed description

Individuals will be followed for up to 1 year to address the following specific aims:

Specific Aim 1: To determine if among individuals diagnosed with hypertensive disorders of pregnancy (HDP), the use of atorvastatin 10 mg daily initiated in the postpartum period following cessation of breastfeeding and continued for 3 months, lowers cardiovascular risk, as measured by the Framingham Risk Score for Cardiovascular Disease (30 year risk, primary outcome) and cardiovascular risk prediction model (PREVENT, secondary outcome) compared with placebo; and if the benefit will persist for at least 3-6 months following discontinuation of atorvastatin treatment.

Specific Aim 2: To determine if among individuals diagnosed with HDP the use of atorvastatin 10 mg daily initiated in the postpartum period following cessation of breastfeeding and continued for 3 months lowers the frequency of metabolic syndrome, improves lipid levels, and reduces inflammatory markers compared with placebo; and if this benefit will persist for at least 3-6 months following discontinuation of atorvastatin treatment.

Specific Aim 3: Determine if circulating extracellular vesicles (EVs) from patients with HDP mediate increased CV risk factors and the potential of EV-based therapeutics to dampen these risk factors. We will isolate plasma-derived EVs from individuals with HDP using retrospective samples and perform in vivo and in vitro functional and metabolic assays. We will also analyze the molecular cargo of EVs isolated from individuals in Aim 1 to identify specific pathways that can be targeted via engineered EVs to attenuate the increased CV risk after HDP.

03

Conditions studied

  • Hypertensive Disorders of Pregnancy
  • Preeclampsia
  • Gestational Hypertension

Keywords

  • Hypertensive disorders of pregnancy
  • Atorvastatin treatment
  • Pregnancy
  • Preeclampsia
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Postpartum
  2. ≥ 20 years old with the ability to give
  3. Diagnosis of gestational hypertension, preeclampsia prior to delivery admission, or diagnosed with preeclampsia during delivery admission, as determined by clinical team using the American College of Obstetricians and Gynecologists (ACOG) criteria.
  4. English speaking

Exclusion criteria

Exclusion Criteria:

  1. Individuals who were prescribed an 3-hydroxy-3 methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor prior to or during pregnancy,
  2. Known familial hypercholesterolemia or pre-existing hyperlipidemia, specifically Low-density Lipoprotein (LDL) >190 prior to pregnancy or diagnosis of hyperlipidemia with prescription of HMG-CoA reductase inhibitor prior to delivery,
  3. Breastfeeding for >= 6 months,
  4. Plan for pregnancy conception in the next 6 months,
  5. Incarcerated individuals,
  6. Hypertensive diagnosis thought to be secondary to fetal condition,
  7. to HMG-CoA reductase inhibitor therapy or known to atorvastatin or any component,
  8. Active liver disease (acute hepatitis, chronic active hepatitis, unexplained persistent transaminitis (at least twice serum transaminases)),
  9. History of rhabdomyolysis or myopathy,
  10. (HIV) positivity, due to potential interactions between atorvastatin and HIV protease inhibitors,
  11. History of solid organ transplant, due to potential interactions between atorvastatin and
  12. Active cancer, or
  13. Current use of medications with potential drug interactions, namely cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors, rifampin, and digoxin.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Active comparator
    10 mg Atorvastatin

    Atorvastatin 10 mg daily for 3 months

    Drug: Atorvastatin 10 mg

  • Placebo comparator
    Placebo

    Identical appearing placebo for 3 months

    Drug: Placebo

Interventions

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be assigned to 10 mg Atorvastatin

  • DrugPlacebo

    Participants will be assigned to identical appearing placebo

06

What researchers measure

Primary outcomes

  1. The 30-year Framingham Risk Score for Cardiovascular Disease

    Predicts 0-100% risk of "hard" CVD events (coronary death, myocardial infarction, stroke) based on sex, systolic blood pressure, antihypertensive treatment, total and high-density lipoprotein cholesterol, smoking, and diabetes mellitus. A higher number reflects a greater risk of adverse CVD events, whereas a lower number reflects lower risk.

    Time frame: After 3 months of study treatment, up to 9 months after enrollment

Secondary outcomes

  1. Drug Use and Side Effects

    Individuals will be contacted monthly via phone call to assess drug tolerability and use using a survey, which reviews any adverse events or concerns related to use of the study drug.

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  2. Framingham Risk Score for Cardiovascular Disease 3-6 months following medication cessation

    Enrolled individuals will be contacted via telephone at 3-6 months after they complete medication use and will be invited to a visit for a Framingham Risk Score calculation. The Framingham Risk Score predicts 0-100% risk of CVD events, with a higher number reflecting a greater risk of adverse CVD events, whereas a lower number reflects lower risk.

    Time frame: Anytime after 3-6 months of stopping to use the study drug, up to 9 months from randomization

  3. PREVENT (AHA Predicting Risk of CVD Events) score

    A glomerular filtration rate will be calculated for each enrolled individual upon enrollment and at the additional biospecimen visits in order to enable calculation of the PREVENT score.

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  4. Rates of primary care provider (PCP) visits within 9-12 months of delivery

    Enrolled individuals will undergo a telephone survey at 9-12 months postpartum, assessing whether they have attended a visit with a primary care provider (internal medicine, family medicine or primary care nurse practitioner), and for what reason, since the time of their delivery

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 12 months from delivery

  5. Waist circumference

    Waist circumference in centimeters will be measured at the study visits to help identify those with metabolic syndrome (circumference of 88 cm or more).

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  6. Fasting glucose

    Fasting glucose levels will be measured at the study visits to help identify those with metabolic syndrome (fasting glucose above or equal to 100 mg/dL).

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  7. Number of individuals diagnosed with metabolic syndrome

    The presence of metabolic syndrome will be defined as 3 or more of the following, which are also listed as individual outcomes: waist circumference greater or equal to 88 cm, triglycerides greater or equal to 150 mg/dL, HDL cholesterol \<50 mg/dL, blood pressure greater or equal to 130/85, and fasting glucose greater or equal to 100 mg/dL.

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  8. Lipid levels

    Serum testing for total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  9. Hypertension diagnosis & need for antihypertensive therapy

    Blood pressure will be measured at the study visits to identify new development of hypertension; enrolled individuals will be asked if they have started medication for hypertension

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  10. Diabetes diagnosis & need for anti-glycemic therapy

    Hemoglobin A1C will be measured at the study visits to identify new development of diabetes mellitus (HbA1C \> 6.5%) and individuals will be asked if they have started anti-glycemic medication

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  11. Systolic blood pressure

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  12. Estimated glomerular filtration rate

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  13. High-sensitivity C-reactive protein (Hs-CRP) level

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  14. Lipoprotein (a) level

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

  15. Apolipoprotein (b) level

    Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months

07

Study locations

1 of 1 sites recruiting
  • The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
    Columbus, Ohio 43210, United States
    Recruiting
    • Maged Costantine, MD, MBA · ContactMaged.Costantine@osumc.edu · 614-293-2222
    • Kara Rood, MD · ContactKara.Rood@osumc.edu · 614-293-8045
    • Kara Rood, MD · Principal investigator
    • Maged Costantine, MD, MBA · Principal investigator
    • Lauren Hassen, MD · Sub investigator
    • Sydney Lammers, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 23 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Oct 9, 2024
StartActual
Oct 3, 2025
Primary completionEst.
Sep 15, 2027was Sep 2026
CompletionEst.
Dec 15, 2027was Dec 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 15, 2026→Sep 15, 2027
Oct 23, 2026
Study completion
Dec 15, 2026→Dec 15, 2027
Oct 23, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedPlan to breastfeedBreastfeeding for >= 6 months,
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Sep 15, 2026→Sep 15, 2027
    Study completion Dec 15, 2026→Dec 15, 2027
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedPlan to breastfeedBreastfeeding for >= 6 months,
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06632379
Responsible party
Tracy Caroline Bank (MD (Fellow), Ohio State University) — Principal investigator
First posted
Oct 9, 2024
Start date
Oct 3, 2025
Primary completion
Sep 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Tracy C Bank, MD
Contact
Tracy.Bank@osumc.edu
614-293-2222
Maged Costantine, MD, MBA
Contact
Maged.Costantine@osumc.edu
614-293-2222
Tracy C Bank, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion